评估聚麦芽糖铁复合物与叶酸（Mumfer）和铁制剂（富马酸亚铁）对女性贫血患者的疗效和安全性。

Evaluation of efficacy and safety of iron polymaltose complex and folic acid (Mumfer) vs iron formulation (ferrous fumarate) in female patients with anaemia.

作者信息

Reddy P S, Adsul B B, Gandewar K, Korde K M, Desai A

机构信息

Department of PSM, LTMM College & LTMG Hospital, Sion, Mumbai.

出版信息

J Indian Med Assoc. 2001 Mar;99(3):154-5.

PMID:11478761

Abstract

Treatment of iron deficiency anaemia with conventional oral preparations is handicapped by unpredictable haematological response in addition to potential for irritating gastrointestinal adverse events. Iron polymaltose complex (IPC), a novel oral iron formulation with better absorbability, predictable haematinic response and less side effects was compared with oral ferrous fumarate in 100 female patients with documented iron deficiency anaemia. Clinical parameters (pallor, weakness) as well as biochemical parameters (Hb, serum iron, total iron binding capacity) show favourable changes with IPC; the physician and patient assessment also favour IPC over ferrous fumarate.

摘要

用传统口服制剂治疗缺铁性贫血存在血液学反应不可预测的问题，此外还可能引发胃肠道不良事件。铁聚麦芽糖复合物（IPC）是一种新型口服铁制剂，具有更好的吸收性、可预测的补血反应和较少的副作用。在100例确诊为缺铁性贫血的女性患者中，将其与口服富马酸亚铁进行了比较。临床参数（面色苍白、虚弱）以及生化参数（血红蛋白、血清铁、总铁结合力）在使用IPC后均呈现出有利变化；医生和患者的评估也表明IPC优于富马酸亚铁。